| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Cancer Research Program, Garvan Institute of Medical Research, St. Vincent’s Hospital, Darlinghurst, Sydney, New South Wales 2010, Australia [R. H., G. L. F., J. S. C., C. S. L. L., E. A. M., R. L. S.], and Department of Medical Oncology, Westmead Hospital, Westmead, New South Wales 2145, Australia [R. H.]
Cyclin D1 and cyclin E are overexpressed in 
45% and 30% of breast cancers, respectively, and adverse associations with patient outcome have been reported. The potential roles of cyclin D1 and cyclin E expression as markers of therapeutic responsiveness to the pure steroidal antiestrogen ICI 182780 were investigated using T-47D breast cancer cell lines constitutively overexpressing cyclin D1 or cyclin E. Measurement of S phase fraction, phosphorylation states of the retinoblastoma protein, and cyclin E-cyclin-dependent kinase (Cdk) 2 activity demonstrated that overexpression of cyclin D1 decreased sensitivity to antiestrogen inhibition at 24 and 48 h. Overexpression of cyclin E produced a less pronounced early cell cycle effect indicating only partial resistance to antiestrogen inhibition in the short-term. In ICI 182780-treated cyclin D1-overexpressing cells, sufficient Cdk activity was retained to allow retinoblastoma protein phosphorylation and cell proliferation, despite an increase in the association of p21 and p27 with cyclin D1-Cdk4/6 and cyclin E-Cdk2 complexes. After longer-term (>7 days) treatment, antiestrogens inhibited colony growth in cyclin D1- or cyclin E-overexpressing breast cancer cells, but with an approximately 2–2.5-fold decrease in dose sensitivity. This was associated with a fall in cyclin D1 levels, a reduction in the half-life of cyclin D1 protein and a decline in cyclin E-Cdk2 activity in cyclin D1-overexpressing cells, and the maintenance of cyclin E-p27 association in the cyclin E-overexpressing cells. These data confirm that cyclin D1 expression and cyclin E-p27 association play important roles in antiestrogen action, and suggest that cyclin D1 or cyclin E overexpression has subtle effects on antiestrogen sensitivity. Additional studies to elucidate the contribution of alterations in cyclin D1 stability to antiestrogen action and to assess the relationship between antiestrogen sensitivity and expression of cyclin D1, cyclin E, or p27 in a clinical setting are required.
This article has been cited by other articles:
|
|
 |
|
  G. HELLER, B. ZIEGLER, A. BRANDSTETTER, S. NOVAK, M. RUDAS, G. HENNIG, M. GEHRMANN, T. ACHT, S. ZOCHBAUER-MULLER, and M. FILIPITS CDK10 Is Not a Target for Aberrant DNA Methylation in Breast Cancer Anticancer Res, October 1, 2009; 29(10): 3939 - 3944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Caldon, C. M. Sergio, J. Schutte, M. N. Boersma, R. L. Sutherland, J. S. Carroll, and E. A. Musgrove Estrogen Regulation of Cyclin E2 Requires Cyclin D1 but Not c-Myc Mol. Cell. Biol., September 1, 2009; 29(17): 4623 - 4639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, J. L. Dean, E. K.A. Millar, T. H. Tran, C. M. McNeil, C. J. Burd, S. M. Henshall, F. E. Utama, A. Witkiewicz, H. Rui, et al. Cyclin D1b Is Aberrantly Regulated in Response to Therapeutic Challenge and Promotes Resistance to Estrogen Antagonists Cancer Res., July 15, 2008; 68(14): 5628 - 5638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rudas, M. Lehnert, A. Huynh, R. Jakesz, C. Singer, S. Lax, W. Schippinger, O. Dietze, R. Greil, W. Stiglbauer, et al. Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy Clin. Cancer Res., March 15, 2008; 14(6): 1767 - 1774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ishii, S. Waxman, and D. Germain Tamoxifen Stimulates the Growth of Cyclin D1-Overexpressing Breast Cancer Cells by Promoting the Activation of Signal Transducer and Activator of Transcription 3 Cancer Res., February 1, 2008; 68(3): 852 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Berglund, M Stighall, K Jirstrom, L Ryden, M Ferno, B Nordenskjold, and G Landberg Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern J. Clin. Pathol., February 1, 2008; 61(2): 184 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. McGowan, A. J. Russell, V. Boonyaratanakornkit, D. N. Saunders, G. M. Lehrbach, C. M. Sergio, E. A. Musgrove, D. P. Edwards, and R. L. Sutherland Progestins Reinitiate Cell Cycle Progression in Antiestrogen-Arrested Breast Cancer Cells through the B-Isoform of Progesterone Receptor Cancer Res., September 15, 2007; 67(18): 8942 - 8951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Deschenes, V. Bourdeau, J. H. White, and S. Mader Regulation of GREB1 Transcription by Estrogen Receptor {alpha} through a Multipartite Enhancer Spread Over 20 kb of Upstream Flanking Sequences J. Biol. Chem., June 15, 2007; 282(24): 17335 - 17339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Kilker and M. D. Planas-Silva Cyclin D1 Is Necessary for Tamoxifen-Induced Cell Cycle Progression in Human Breast Cancer Cells Cancer Res., December 1, 2006; 66(23): 11478 - 11484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J-R Weng, C-Y Chen, J J Pinzone, M D Ringel, and C-S Chen Beyond peroxisome proliferator-activated receptor {gamma} signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr. Relat. Cancer, June 1, 2006; 13(2): 401 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J Butt, C. M McNeil, E. A Musgrove, and R. L Sutherland Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S47 - S59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-W. Huang, C.-W. Shiau, Y.-T. Yang, S. K. Kulp, K.-F. Chen, R. W. Brueggemeier, C. L. Shapiro, and C.-S. Chen Peroxisome Proliferator-Activated Receptor {gamma}-Independent Ablation of Cyclin D1 by Thiazolidinediones and Their Derivatives in Breast Cancer Cells Mol. Pharmacol., April 1, 2005; 67(4): 1342 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Alao, E. W-F. Lam, S. Ali, L. Buluwela, W. Bordogna, P. Lockey, R. Varshochi, A. V. Stavropoulou, R. C. Coombes, and D. M. Vigushin Histone Deacetylase Inhibitor Trichostatin A Represses Estrogen Receptor {alpha}-Dependent Transcription and Promotes Proteasomal Degradation of Cyclin D1 in Human Breast Carcinoma Cell Lines Clin. Cancer Res., December 1, 2004; 10(23): 8094 - 8104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Akli, P.-J. Zheng, A. S. Multani, H. F. Wingate, S. Pathak, N. Zhang, S. L. Tucker, S. Chang, and K. Keyomarsi Tumor-Specific Low Molecular Weight Forms of Cyclin E Induce Genomic Instability and Resistance to p21, p27, and Antiestrogens in Breast Cancer Cancer Res., May 1, 2004; 64(9): 3198 - 3208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Strom, J. Hartman, J. S. Foster, S. Kietz, J. Wimalasena, and J.-A. Gustafsson Estrogen receptor {beta} inhibits 17{beta}-estradiol-stimulated proliferation of the breast cancer cell line T47D PNAS, February 10, 2004; 101(6): 1566 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Q. Kemp, B. D. Jeffy, and D. F. Romagnolo Conjugated Linoleic Acid Inhibits Cell Proliferation through a p53-Dependent Mechanism: Effects on the Expression of G1-Restriction Points in Breast and Colon Cancer Cells J. Nutr., November 1, 2003; 133(11): 3670 - 3677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ellis, A. Coop, B. Singh, Y. Tao, A. Llombart-Cussac, F. Janicke, L. Mauriac, E. Quebe-Fehling, H. A. Chaudri-Ross, D. B. Evans, et al. Letrozole Inhibits Tumor Proliferation More Effectively than Tamoxifen Independent of HER1/2 Expression Status Cancer Res., October 1, 2003; 63(19): 6523 - 6531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Lapillonne, M. Konopleva, T. Tsao, D. Gold, T. McQueen, R. L. Sutherland, T. Madden, and M. Andreeff Activation of Peroxisome Proliferator-activated Receptor {gamma} by a Novel Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid Induces Growth Arrest and Apoptosis in Breast Cancer Cells Cancer Res., September 15, 2003; 63(18): 5926 - 5939. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
